http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Abbott Receives FDA Approval for the FreeStyle Libre Pro™ System, a Revolutionary Diabetes Sensing Technology for Healthcare Professionals to Use with Their Patients
-
Abbott's (ABT) PLOS ONE Study Says Malnutrition Adds $15.5B to U.S. Spending Each Year
-
Malnutrition Adds $15.5 Billion Annually to Direct U.S. Medical Costs
-
Abbott Hosts Conference Call for Third-Quarter Earnings
-
Fueling Performance with Fat: EAS® Launches First Ketogenic Meal Replacement For Athletes
-
Abbott (ABT) to Sell Abbott Medical Optics to Johnson & Johnson (JNJ) in $4.33B Deal
-
Abbott to Sell Abbott Medical Optics to Johnson & Johnson for $4.325 Billion
-
Abbott Declares 371st Consecutive Quarterly Dividend
-
Abbott Named Industry Leader for Responsible and Sustainable Business for Four Consecutive Years on the Dow Jones Sustainability Index (DJSI)
-
Abbott Named Industry Leader for Responsible and Sustainable Business for Four Consecutive Years on the Dow Jones Sustainability Index (DJSI)
-
Abbott to Present at Wells Fargo Healthcare Conference
-
Abbott Unveils Alinity™, its Unified Family of Innovative Next-Generation Diagnostics Systems
-
Abbott Reports Second-Quarter 2016 Results
-
Abbott (ABT) Receives FDA Approval for Tecnis Symfony as Treatment of Cataracts
-
FDA Approves the Tecnis Symfony® Intraocular Lenses, the First and Only Extended Depth of Focus Lenses for People with Cataracts
-
Abbott (ABT) Announces FDA Approval of Absorb Bioresorbable Stent
-
FDA approves Abbott's Absorb™ bioresorbable stent, the only fully dissolving heart stent
-
Abbott Hosts Conference Call for Second-Quarter Earnings
-
Abbott's (ABT) IMPACT Trial of FreeStyle Libre System Met Primary Endpoint as T1D Treatment
-
Abbott Announces Positive Results from Groundbreaking Study of FreeStyle® Libre System for People with Type 1 Diabetes
-
Abbott Declares 370th Consecutive Quarterly Dividend
-
New Curate™ Kids Combines Wholesome Ingredients and Kid-Friendly Flavors to Help Parents Win Snack-time
-
A Clever Way to Add Nutrition to Your Toddler's Favorite Foods: Go & Grow by Similac® Food Mix-Ins™
-
Abbott Announces Positive Results from Pivotal Study of Tecnis® Symfony IOL for Cataract Surgery
-
Abbott to Present at Deutsche Bank Health Care Conference
-
America's Health Check-up: AARP and Abbott Survey Finds Half of Adults 50-Plus Wish They Had More Strength and Energy to Enjoy Daily Activities
-
Abbott (ABT) to Acquire St. Jude Medical (STJ) in ~$31B Deal
-
Abbott to Acquire St. Jude Medical
-
What's the Secret to Living a Full Life? A New Global Survey Reveals Family Comes First
-
Abbott Introduces New Services and Tools to Help Labs Deliver Greater Operational Productivity
-
Abbott Reports First-Quarter 2016 Results
-
Abbott Launches EAS® Myoplex® Sports Nutrition Line Designed for Performance
-
New Research Shows Abbott's High Sensitive Troponin Test First to Measure Impact of Mental Stress on the Heart
-
Abbott Introduces Ensure® Enlive®, Pairing the Latest in Science and Nutrition to Improve Health
-
Abbott Hosts Conference Call for First-Quarter Earnings
-
Abbott (ABT) Announces Positive FDA Advisory Committee Review of Absorb
-
Abbott's Absorb™, the First Fully Dissolving Heart Stent, Earns Positive Review by FDA Advisory Committee
-
Abbott to Present at Barclays Capital 2016 Global Healthcare Conference
-
Abbott, Hennepin County Medical Center and University of Minnesota Collaborate to Launch the Nation's Largest, Single-Center Prospective Study on Concussion and Traumatic Brain Injury
-
Eliud Kipchoge and Mary Keitany Win Abbott World Marathon Series IX
-
Abbott Declares 369th Consecutive Quarterly Dividend
-
Abbott Receives Approval in Australia for FreeStyle® Libre--the Revolutionary Glucose Monitoring System for People with Diabetes
-
Abbott Introduces New 'Foodie' Inspired Snack Brand: Curate
-
Children in Europe Now Have Access to First-Of-Its-Kind Diabetes Sensing Technology - Eliminates Routine Finger Pricks(i)
-
Pre-Open Stock Movers 02/01: (ALR) (STR) (TROV) Higher; (GPRO) (TSLA) (D) Lower (more...)
-
Abbott (ABT) to Acquire Alere (ALR) for $56/Share
-
Abbott to Acquire Alere, Becoming Leader in Point of Care Testing and Significantly Advancing Global Diagnostics Presence
-
Abbott Reports Fourth-Quarter 2015 Results
-
Abbott (ABT) Announces Publication of Positive NOURISH Study Data
-
Specialized nutrition supplement is associated with a 50 percent lower death rate in patients with heart or lung disease, new study shows

